Innovative therapeutics

About us

Jean-Jacques Bienaime

Chairman and Chief Executive Officer

Jean-Jacques Bienaimé - BioMarin Chairman and Chief Executive OfficerJean-Jacques Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors, bringing with him more than 25 years of experience in the biotechnology and pharmaceutical industries. He was named Chair of the Board in June 2015. Under Mr. Bienaimé’s leadership, the market capitalization of BioMarin grew to approximately more than $16 billion at the end of 2015 from around $450 million in May 2005.

In 2015, Ernst & Young recognized Mr. Bienaimé with the Entrepreneur of the Year Award in the Health and Life Sciences category Northern California.

From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor’s revenues increased to more than $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of more than $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. He guided Sangstat to profitability prior to its acquisition by Genzyme Corporation.

From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the boards of Incyte Corporation, a public pharmaceutical company, and Vital Therapies, Inc., a public biotechnology company, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association. He received an M.B.A. from the Wharton School at the University of Pennsylvania, and a degree in economics from the École Supérieure de Commerce de Paris.

-Updated April 2016

Providing promising new therapeutics to patients with severe or life-threatening diseases.

learn more

Vimizim
Click here to learn more about Vimizim (elosulfase alfa), including full prescribing information and boxed warning.

prod2
Click here to learn more about Naglazyme (galsulfase), including full prescribing information.

prod3
Click here to learn more about Aldurazyme (laronidase),
including full prescribing information and black box warning.

prod1
Click here to learn more about Kuvan (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution, including full prescribing information.

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information

Top